Medical Device Maker **Boston Scientific** (NYSE: BSX) trades at **$42.98** ($62.3B market cap), down over **58%** from its 52-week high of $105.65. The sell-off has driven BSX’s standard valuation multiples to multi-year lows, conflicting sharply with its underlying operational performance.
[https://i.imgur.com/L6hmxjB.png](https://i.imgur.com/L6hmxjB.png)
The recent insider activity in Boston Scientific (BSX) reveals an aggressive **cluster of open-market purchases** between May and August 2026, marking a complete reversal from the routine executive selling observed in 2025 and early 2026.
[http://openinsider.com/search?q=bsx](http://openinsider.com/search?q=bsx)
* **High-Conviction CEO Buy:** The most significant signal is CEO Michael Mahoney’s open-market purchase of **186,240 shares for \~$9.0M** at an average price of $48.33 on August 3, 2026. When an executive who previously engaged in planned Rule 10b5-1 sales above $100 commits personal capital at this magnitude, it demonstrates strong conviction.
* **Cluster Buying Across the Board:** Rather than an isolated trade by a single individual, **four separate board members** (Habiger, Ludwig, Morano, and Pegus) simultaneously stepped in to purchase shares with their own funds across two distinct windows (May and late July/August 2026). Cluster buying across multiple directors is statistically one of the strongest insider bullish indicators.
* **Capitalizing on Short-Term Disruption:** Insiders concentrated their accumulation in the **$45.00–$49.50 range** following the stock's plunge from its highs near $108. This points to internal confidence that recent operational noise—such as system/shipping disruptions and valuation compression—is temporary, while core fundamentals (double-digit top-line growth and a 21% operating margin) remain intact.
* **Aligned with Corporate Capital Allocation:** This insider buying coincided with Boston Scientific board authorization of a new **$5.0B share repurchase authorization** (including an initial $2.0B accelerated buyback program), confirming that both management and the board view the stock as undervalued.
